SER100 in Isolated Systolic Hypertension

A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01987284

Enrollment

Registered

2013-11-19

Start date

2013-10-31

Completion date

2014-09-30

Last updated

2016-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Isolated Systolic Hypertension

Brief summary

Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly people. Much attention has recently been drawn to the strong relationship between the systolic blood pressure and cardiovascular morbidity. In previous clinical studies carried out in individuals with normal blood pressure at baseline SER100 decreased primarily the systolic blood pressure. It is hypothesized that the effect on systolic blood pressure in hypertensive patients will be larger or equal to the fall seen in normotensive patients.

Interventions

DRUGSER100

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

50 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Mean systolic blood pressure ≥ 150 mmHg and mean diastolic blood pressure \< 90 mmHg - as determined by daytime continuous ambulatory blood pressure measurement (ABPM) * Male or female * Age 50-80 years (both inclusive) at screening * Patients must be on stable doses with one or more antihypertensives * BMI \<32 kg/m2 * Written informed consent

Exclusion criteria

* Acute myocardial infarction in the last 6 months before screening * Stroke in the last 6 months before screening * Uncompensated heart failure (NYHA Class IV) * Angina pectoris with an anticipated need for administration of short-acting nitrates * Known, severe sleep apnoea * Abnormal laboratory values (i.e. \> 2 x upper normal limit) at screening * Subjects working night shifts (11 PM to 7 AM) * Participation in any other clinical trial with an investigational medicinal product or device within 1 month prior to randomisation. * Subjects with upper arm circumference ≤24 cm or ≥ 42 cm. * Any general condition, serious disease or current evidence of any mental or physical disorder or collaboration attitude (e.g. dementia, substance abuse) which, in the judgment of the investigator makes the subject unsuitable for enrollment, and/or may interfere with the study evaluations or affect subject's safety and/or may cause risk for poor protocol compliance * Pregnant or lactating women. * Female subjects of childbearing potential, or male subjects whose female partner (unless post-menopausal for 1 year or surgically sterile) is unwilling to use adequate contraceptive measures throughout the duration of the study

Design outcomes

Primary

Measure	Time frame
Number of participants with adverse events	Up to 4 weeks

Secondary

Measure	Time frame
Change from baseline in systolic blood pressure	Up to 4 weeks

Countries

Finland, Hungary, Norway, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026